Intco Medical Technology (300677) Fundamentals 2026 — P/E 44.3x, Revenue Analysis | SniperIQ
Intco Medical Technology (300677) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥30.7B, trading at ¥46.95 on the SHZ. This SniperIQ fundamentals page covers Intco Medical Technology's valuation (P/E 44.3x, P/B 1.3x), profitability (net margin 6.5%), revenue (¥9.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Intco Medical Technology's market cap?
Intco Medical Technology (300677) has a market capitalization of approximately ¥30.7B, trading at ¥46.95 on the SHZ. Market cap moves with the live share price.
What is Intco Medical Technology's P/E ratio?
Intco Medical Technology's trailing twelve-month P/E ratio is 44.3x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Intco Medical Technology?
Intco Medical Technology runs a net profit margin of 6.5%, a gross margin of 24.7%, and an operating margin of 8.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Intco Medical Technology generate?
Intco Medical Technology reported revenue of ¥9.9B for fiscal year 2025, with net income of ¥1.0B and earnings per share (EPS) of 1.58. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Intco Medical Technology pay a dividend?
Intco Medical Technology offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Intco Medical Technology financially healthy?
Intco Medical Technology carries a debt-to-equity ratio of 0.97x and a current ratio of 0.84x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Intco Medical Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Intco Medical Technology (300677) the key facts are: market cap ¥30.7B, P/E 44.3x, revenue ¥9.9B, 52-week range 29.84-68.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Intco Medical Technology's full fundamentals live
Get Intco Medical Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.